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The UK Food Standards Agency convened a group of expert scientists to review current research investigating emerging diet-related sur-
rogate end points for colorectal cancer (CRC). The workshop aimed to overview current research and establish priorities for future
research. The workshop considered that the validation of current putative diet-related surrogate end points for CRC and the development
of novel ones, particularly in the emerging fields of proteomics, genomics and epigenomics, should be a high priority for future research.
Colorectal cancer: Diet: Food Standards Agency: Biomarkers: Surrogate end points
On 14 February 2003, the UK Food Standards Agency
(FSA) convened a workshop on emerging diet-related sur-
rogate end points for colorectal cancer (CRC). The results
from recently completed studies and details from ongoing
studies were presented (both FSA- and non-FSA-funded).
The workshop was chaired by Professor Joseph Rafter
(Karolinska Institute, Sweden). The aim of the workshop
was to determine where further work should be concen-
trated, as well as acting as a vehicle for dissemination.
The research recommendations will feed into the future
direction of FSA-funded nutrition research, and may also
be of value in guiding other funding agencies.
CRC is the second most common cancer in men and
women in the UK, only surpassed by lung and breast
cancers respectively. While a small proportion (,5 %) of
CRC is attributable to familial cancer syndromes (familial
adenomatous polyposis and hereditary non-polyposis
CRC), the majority appear to arise sporadically. There is
strong epidemiological evidence for environmental factors
in the development of sporadic CRC. There are substantial
numbers of dietary factors, and factors related to the diet,
which may modify the risk of CRC, e.g. vegetable-rich
diets are thought to be protective (Baron, 2001). The mech-
anisms by which dietary factors can alter the risk, however,
and a clear causal link between diet and the risk of CRC,
are yet to be fully established.
Intervention studies or prospective observational epide-
miological studies that use incident cancer as an end
point are large, lengthy and costly. For this reason, studies
with surrogate end points, biomarkers of preclinical car-
cinogenesis, are attractive: they are potentially smaller,
shorter and less costly. Studies based on such surrogate
end points are, however, inherently less informative than
studies with the ‘true’ end point (e.g. incident cancer,
cancer recurrence or cancer mortality).
The UK FSA Diet and Colonic Health research
programme’s initial focus is the development of validated
diet-related surrogate end points for CRC risk; once these
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have been established they will be used in dietary
intervention trials.
Background
Most cases of sporadic CRC are believed to develop via the
adenoma–carcinoma sequence: although not proved
directly, this is supported by a considerable body of
indirect evidence: epidemiological, clinical, histopathologi-
cal and genetic studies (Leslie et al. 2002). This underpins
the use of adenomatous polyp (adenoma) recurrence and
regression in high-risk populations as a surrogate outcome
for CRC. Only a small proportion of adenomas, however,
progress to cancer (Leslie et al. 2002). It is unlikely that
there would be a definitive clinical trial of dietary factors
for the primary or secondary prevention of CRC, because
a large sample and long follow-up would be required,
and adenoma occurrence is generally regarded as a valid
surrogate end point (Baron, 2001).
Germline mutations in APC and DNA mismatch repair
genes (e.g. hHLM) are responsible for familial adenoma-
tous polyposis and hereditary non-polyposis CRC respect-
ively (Leslie et al. 2002); somatic mutations occur in these
genes in a high proportion of sporadic CRC. A multistep
model for the genetic events in the progression of sporadic
CRC has been proposed (Vogelstein et al. 1988).
Underlying genetic alterations have been described in
three classes of gene: tumour suppressor (e.g. p53, APC)
and DNA repair genes (e.g. hMLH, MYH) and oncogenes
(e.g. K-ras) (Vogelstein et al. 2000). It has been suggested
that the accumulation, rather than the specific nature and
temporal order, of mutations is responsible for tumour
development (Kinzler & Vogelstein, 1996); a recent
study revealed the heterogenous nature of APC, K-ras
and p53 tumour mutation patterns, suggesting multiple
genetic pathways to CRC (Smith et al. 2002).
Mucosal homeostasis requires a balance between
proliferation and apoptosis (Bedi et al. 1995), and it is
thought that an imbalance in the mucosa gives rise to
adenomas. Field effects (an imbalance in mucosal homeosta-
sis affecting the whole colorectal mucosa) may long
predate the emergence of identifiable focal lesions. Apopto-
sis activity in the normal rectal mucosa has been shown to be
negatively associated with adenomas elsewhere in the colon,
consistent with the existence of a field effect (Martin et al.
2002). Normal mucosal proliferation rates, however, have
not been shown to be associated with adenoma development
(Keku et al. 1998; Sandler et al. 2000; Martin et al. 2002). In
another recent study, apoptotic activity in the flat mucosa was
lower in patients with colonic neoplasia than in individuals
without (Bernstein et al. 2002). Dietary factors may modu-
late the vulnerability of the colorectal mucosa at these
early stages (Johnson, 2002); however, the mechanisms
underlying pre-neoplastic changes in the mucosa are poorly
defined.
Epigenetic indicators
Epigenetic mechanisms do not involve alterations to the
DNA sequence, but cause somatic cells to acquire changes
in gene expression that are transmissible through mitosis.
A variety of regulatory proteins including DNA methyl-
transferases, methyl-CpG (the covalent binding of a
methyl group to the 50 position of a cytosine nucleotide
adjacent to a guanine nucleotide) binding proteins, his-
tone-modifying enzymes, and chromatin remodelling fac-
tors and their multi-molecular complexes are involved in
the overall epigenetic process. Epigenetic events are sus-
ceptible to change and may be involved in the mechanisms
by which environmental factors modify cancer risk.
DNA methylation (CpG) is an important epigenetic
feature of DNA, shown to regulate gene expression
(Jones & Takai, 2001) and chromosomal stability (Chen
et al. 1998). The supply of methyl groups for the formation
of S-adenosylmethionine, DNA methyltransferase activity
and DNA demethylation activity could all affect the
extent of DNA methylation.
Abnormal DNA methylation patterns are evident in most
cancers, including colon, lung, prostate and breast cancer;
global DNA hypomethylation, accompanied by gene-
specific hypermethylation, is a common characteristic
among tumour cells (Baylin et al. 1998). Global DNA
hypomethylation has been associated with genetic instabil-
ity (Chen et al. 1998). Interestingly, gene-specific hyper-
methylation in normal colorectal mucosa has been shown
to be positively associated with age (Ahuja et al. 1998),
although considerable individual variation was also
observed.
Gene-specific hypermethylation of CpG islands (CpG-
rich sequences located in the promoter region or first
exon of genes) is associated with the inactivation of vir-
tually all pathways involved with the cancer process,
including DNA repair (e.g. hMLH1, MGMT), cell cycle
regulation (e.g. p16 INK4a), inflammatory and/or stress
response (e.g. COX-2) and apoptosis (e.g. DAPK, APAF-
1) (Jubb et al. 2001). Unlike the cytosines elsewhere in
the genome, CpG islands are normally completely
unmethylated in expressed genes.
Alterations in the degree of CpG-island methylation regu-
late gene promoter regions by modifying the binding of
transcription factors and methyl-DNA binding proteins
(Jubb et al. 2001). Aberrant methylation of CpG islands
in the promoter region has been shown to contribute to the
genetic dysfunction associated with CRC, e.g. in the
HPP1 (Sato et al. 2002), hMLH1 (Herman et al. 1998;
Ricciardiello et al. 2003) and APC genes (Esteller et al.
2000). Silencing of the DNA repair gene hMLH1 in adeno-
mas by promoter methylation is strongly associated with
microsatellite instability in sporadic CRC (Ricciardiello
et al. 2003). In colorectal tumours, promoter hypermethyla-
tion of the DNA repair gene O 6-methylguanine-DNA
methyltransferase (MGMT) is associated with the presence
of G:G to A:T transition mutations in p53 and K-ras (Estel-
ler et al. 2000, 2001).
Aberrant CpG methylation has also been demonstrated
in adenomas (Rashid et al. 2001), suggesting the early
role of methylation in colorectal tumourigenesis. Whether
aberrant CpG methylation underlies field effects remains
to be determined; however, it has been shown that age-
related methylation of the CpG islands of the hMLH1 pro-
moter does occur in the apparently normal mucosa of
patients with CRC, and this abnormality is associated
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with microsatellite instability (Nakagawa et al. 2001).
Cancer has, therefore, become to be understood as both a
genetic and epigenetic disease with complex connections
between the pathways.
Various nutrients appear to affect DNA methylation
status, including Se (Davis et al. 2000), folate, vitamin
B12 and choline (Johanning et al. 2002), methionine
(Rowling et al. 2002a), retinoic acid (Rowling et al.
2002b) and isoflavones (Day et al. 2002). Interestingly, his-
tone acetylation, another related epigenetic event, is
potently inhibited in vitro by butyrate (Hinnebusch et al.
2002), modified by dietary fibre in vivo (Boffa et al.
1992) and associated with marked changes in gene
expression (Williams et al. 2003).
Professor Ian Johnson presented results from an FSA-
funded pilot project in collaboration with Newcastle
University (NJ Belshaw, GO Elliott, EA Williams, DM
Bradburn, SJ Mills and JC Mathers, unpublished results),
performed using mucosal biopsies, tumour tissue and
faecal samples obtained from consenting gastrointestinal
cancer patients. Methods were developed for extraction
of faecal DNA and application of methylation-specific
PCR (highly sensitive) and combined bisulfite restriction
analysis (quantitative). Analysis was performed on six
genes known to be involved in adenoma–carcinoma
sequence, and/or previously reported to be partially
methylated in the flat mucosa of older patients (ESR1,
APC, hMLH1, HPP1, P16, MGMT). The results and con-
clusions were:
. faeces are a practical source of DNA for methylation
studies;
. refined combined bisulfite restriction analysis assay
provides quantitative estimates of the extent of methyl-
ation at specific sites in genes even at low levels of
methylation;
. methylation varied significantly and consistently
between genes;
. methylation of most, but not all, target genes was
enriched in the faecal DNA;
. ESR1 and MGMT both showed substantial levels of
methylation in the promoter regions, detectable in
DNA in stool. For ESR1 there was a statistically signifi-
cant correlation between the levels of methylation
measured in the faecal DNA, and those in the morpho-
logically normal mucosa.
The use of faecal DNA samples to detect and quantify
DNA methylation in a range of target genes might provide
a valuable non-invasive marker of pre-cancerous changes;
this marker could be applied in epidemiological studies
at the population level. These preliminary observations
are now being followed up in a further FSA-funded project
that will define CpG-island methylation patterns in a much
larger set of genes. Faecal samples are being obtained from
both healthy volunteers with widely differing ages, and
from patients with well-defined gastrointestinal
abnormalities.
In a parallel project, workers the Institute of Food
Research (Norwich, Norfolk, UK) and Newcastle
University are using two-dimensional gel electrophoresis
and MS to characterise the patterns of protein expression
in the apparently normal mucosa of human volunteers,
with and without evidence of colorectal neoplasia. The
objective is to identify consistent differences in gene trans-
lation associated with mucosal field changes, to search for
possible epigenetic mechanisms underlying such differ-
ences and to provide further novel biomarkers of early
neoplasia.
Professor John Mathers and Dr Hilary Powers presented
details of an ongoing FSA-funded double-blind randomised
controlled trial in subjects with no evidence of bowel path-
ology and in those at enhanced risk of CRC because they
carry one or more adenomatous polyps. The aim is to recruit
120 subjects per group. Subjects are randomised to one of
four interventions: placebo, 400mg folic acid/d, 1200mg
folic acid/d, 400mg folic acid plus 5 mg riboflavin/d.
Blood and colonic mucosal biopsies will be collected at
baseline and after 6–8 weeks of intervention for assay of:
. biochemical indices of folate status in blood and in
mucosa;
. uracil mis-incorporation (a form of damage to DNA);
. whole genome methylation and methylation at specific
sites in a panel of CRC-related genes e.g. hMLH1, APC
and HPP1.
Because of the interaction between methyl donor status
and the common C677T polymorphism in the folate-meta-
bolising gene MTHFR on risk of CRC, volunteers will be
stratified for this polymorphism. For comparative purposes,
baseline measurements are being made on an additional
cohort of 120 CRC patients.
Dr Hilary Powers presented preliminary results (MH
Hill, HJ Powers, EA Williams, W Bal & M Welfare,
unpublished results) from twenty-eight subjects, examining
both the responses to intervention in various biochemical
measures of folate and riboflavin status and associations
between responses in mucosal tissue and plasma.
5-Methyl tetrahydrofolate was determined in small
amounts of flat mucosal colonic biopsy material, by homo-
genisation in ascorbic acid followed by protein precipi-
tation, and analysis by reverse-phase HPLC with
fluorescence detection. The main results were:
. plasma 5-methyltetrahydrofolate concentrations
increased from an average of 41·4 (SD 23·7) to 74·7
(SD 38·8) nmol/l over the period of intervention, and
mucosal 5-methyltetrahydrofolate increased from 0·44
(SD 0·33) to 0·80 (SD 0·39) nmol/g tissue. Riboflavin
status also improved, showing a change in erythrocyte
glutathione reductase activation coefficient from a
mean value of 1·41 (SD 0·12) to 1·30 (SD 0·13);
. at baseline there was a significant association between
plasma homocysteine and plasma 5-methyl tetrahydrofo-
late (P¼0·028), and also between plasma homocysteine
and mucosal 5-methyltetrahydrofolate (P¼0·001). A
strong positive association was evident between the
change in mucosal and plasma 5-methyl tetrahydrofolate
(P¼0·025).
The concentration of 5-methyltetrahydrofolate deter-
mined in colonic mucosa was comparable with total folates
reported in patients with colorectal polyps (Kim et al.
1998). Results at this early stage in the intervention
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(before breaking the randomisation code) support the use
of plasma measurements of folate status as a surrogate
of responsiveness of colonic mucosa to folate supple-
mentation. Other workers have suggested that in the face
of very-high-folate supplements, neither erythrocyte nor
plasma folate will accurately reflect colonic
mucosal folate (Kim et al. 2001).
Angela McGlynn and Rae Dare presented details of
FSA-funded projects from Professor Stephen Downes’ lab-
oratory, employing comet assays and microarray tech-
niques to quantify global and gene-specific DNA
methylation status of colon cells, and to determine whether
these patterns of methylation can be modified by folate
supplementation.
The alkaline comet assay, originally used to measure
DNA damage, was developed, by the use of methylation
specific endonucleases Hpa II and Hha I, to determine the
global DNA methylation status of single colonic cells
derived from small human biopsies. The endonucleases
specifically cleave unmethylated DNA, giving rise to
DNA strand breaks and a comet tail after electrophoresis.
The level of DNA in the comet tail is therefore indicative
of the degree to which the DNA in that particular cell is
hypomethylated. The methylation–comet analysis is cur-
rently being performed on cells derived from three separate
sites of the colon, including tumour or polyp sites and sites
adjacent and distal to either, in an ongoing folate interven-
tion study with human subjects.
The combination of fluorescence in situ hybridisation
(FISH) of DNA sequences with the methylation–comet
assay has been developed to measure p53 gene-specific
methylation. Comparison of the number of FISH hybridis-
ation spots in the comet head (unbroken methylated DNA)
compared with those in the comet tail (digested hypo-
methylated DNA) allows some measure of the degree of
hypomethylation in the p53 region, specific to the FISH
probe. Folate-depleted colonic cell lines showed increased
hypomethylation in the p53 region. This comet–FISH
method was also applied successfully to a small number
of human biopsy samples. p53 gene comet–FISH is
currently being further optimised with the design of FISH
probes that are entirely specific to the p53 gene.
Several molecular techniques have been developed to
analyse the methylation status of DNA. While sodium
bisulfite sequencing is seen as the ‘gold standard’, there
are also a number of other related PCR-based techniques.
These approaches usually involve the investigation of a
single CpG island, and thus studies using these approaches
are limited due to the complex epigenetic nature of
cancers.
Microarrays are commonly used to provide information
on the expression of tens of thousands of genes. Alterna-
tively, microarrays can also be used to provide information
on the methylation status of DNA. Microarray analysis
enables investigation of methylation on a global scale, and
allows for high-throughput analysis. There are
currently two main techniques for microarray methylation
analysis: methylation-specific oligonucleotide (Gitan et al.
2002) and differential methylation hybridisation
microarrays (Yan et al. 2002). Methylation-specific
oligonucleotide arrays are capable of differentiating
methylated and unmethylated CpG sites at specific locations
of a promoter, while differential methylation hybridisation
arrays allow the methylation status of multiple CpG islands
to be determined.
Diet and genetic susceptibility
Dr Ellen Kampman presented preliminary results from an
ongoing Dutch case–control study conducted at Wagenin-
gen University and Research Centre in collaboration with
University Medical Centre Nijmegen (Dr Fokko
Nagengast) and regional hospitals to investigate the inter-
play between diet and genetic susceptibility on risk of colo-
rectal adenomatous polyps. All cases with adenomatous
polyps and polyp-free controls filled out the EPIC food-fre-
quency questionnaire, and blood samples were collected
for evaluation of biomarkers of exposure (e.g. folate
status, fatty acid profiles) and genotyping. In a subgroup
of the participants, fat aspirates were collected to assess
internal exposure, e.g. to fatty acids and antioxidants.
Genetic variants in metabolising enzymes (e.g. coding
region polymorphisms in alcohol dehydrogenases,
N-acetyl-transferases, glutathione S-transferases (GST),
sulfotransferases, microsomal epoxide hydrolase, methylte-
trahydrofolatereductase and cyclooxygenases) are being
determined. DNA extracted from paraffin-embedded
adenoma tissue will be assessed for somatic mutations in
tumour suppressor genes and oncogenes as well as for
the methylation status of specific genes in collaboration
with University Medical Centre Nijmegen and Maastricht
University respectively.
. Preliminary results of this study are consistent with the
findings of others showing an increased risk of adeno-
mas with smoking, alcohol consumption, and, although
not statistically significant, meat consumption
(Tiemersma et al. 2002). Alcohol consumption
especially increased risk among those with the
ADH3*1/*1 genotype (Tiemersma et al. 2003). Inverse
associations were observed for aspirin use and con-
sumption of dairy foods. Vegetable and fruit consump-
tion do not appear to markedly influence overall
adenoma risk in this study. Preliminary analyses includ-
ing 495 cases and 510 controls also showed no signifi-
cant associations with folate intake, stratifying for the
MTHFR 677 polymorphism and adjusting for age,
sex, indication for endoscopy, and intake of total
energy and dietary fibre. Analyses will be finalised
with data from more than 600 cases and 600 controls.
Sub-site analyses, and analyses taking the size,
number and histology of the adenomas into account
will be conducted.
Among the adenoma cases, an intervention trial is
ongoing to assess whether supplementation with folic
acid (5 mg/d) and cyanocobalamin (1·25 mg/d) alters
gene-specific DNA methylation in the colon differently
for those with the MTHFR-TT and MTHFR-CC 677 geno-
type (Van den Donk et al. 2002). Blood samples as well as
colonic biopsies were collected at the beginning and after
6 months supplementation. In a subgroup, mucosal
proliferation, apoptosis and the expression of selective
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response genes, as identified by in vitro experiments,
will be evaluated. Ongoing experimental research at
Wageningen University also focuses on polymorphisms
in the antioxidant-response–electrophile-response elements
in the promoter region of GST and NAD(P)H:quinone
oxidoreductases and inducibility by plant foods.
The antioxidant-response–electrophile-response ele-
ments-signalling pathway appears to upregulate expression
of several phase II detoxifying enzymes and affects p53
stabilisation in response to stress. Induction of phase II
detoxifying enzymes, such as GST and NAD(P)H:quinone
oxidoreductases, leads in general to protection of cells and
tissues against exogenous and/or endogenous carcinogenic
intermediates. Compounds found in plant foods, e.g. flavo-
noids and isothiocyanates (a gut breakdown product of
glucosinolates found in cruciferous vegetables) have
been shown to induce phase II detoxifying enzymes
(see Johnson, 2002; Lampe & Peterson, 2002).
GST are a super-family of phase II enzymes that may
contribute to resistance against oxidative stress (Hayes &
Strange, 1995). The best-characterised GST isoenzymes
in mammals have been grouped into four major classes,
termed alpha (a), pi (p), mu (m), and theta (u), but
additional forms exist. Null genotypes for GSTM1 and
GSTT1 occur in frequencies of approximately 50 and
20 % of the population respectively and result in absence
of the respective enzymes. Although no overall associ-
ations between GSTM1, T1 or P1 genotypes and CRC
risk have been observed, a recent nested case–control
study (Seow et al. 2002) found a significant reduction in
CRC risk among individuals with both GSTM1 and
T1 null genotypes with a high v. low dietary intake of
isothiocyanates. Lampe et al. (2000) observed that serum
GSTa concentration increased significantly in response to
cruciferous vegetable feeding, but only in GSTM1-null
individuals (Lampe et al. 2000). Overall, this suggests
that GST genetic polymorphisms influence the relationship
between cruciferous vegetable intake and cancer risk
(Lampe & Peterson, 2002).
Professor Beatrice Pool-Zobel presented results from
studies investigating the effects of nutritional components
on expression of GST, and on damage to DNA, in
human primary colon cells, human colonic adenoma
cells (LT97) and a human colon tumour cell line (HT29)
(Scha¨ferhenrich et al. 2003a,b). The pre-neoplastic lesions
that occur in LT97 are also observed at increasing fre-
quency with increasing age in the general population.
Oxidative stress and resulting lipid peroxidation
are possible risk factors for diet-related colon cancer
(Pool-Zobel et al. 1999; Liegibel et al. 2000); however,
the risk potential needs to be characterised. The genotoxic
effects of 4-hydroxy-2-nonenal (HNE; a lipid peroxidation
product), H2O2, the induction of GST (Ebert et al. 2001) by
butyrate (a gut bacteria carbohydrate-fermentation
product), complex fermentation products (e.g. products
produced in vitro after incubating dietary fibres and
faecal slurries) and selected phytoprotectants (catechins
of green tea, isoflavonoids) were investigated. Butyrate is
found in mmol concentrations in the gut lumen and
serves as a principal energy source for colon epithelial
cells (Roediger, 1989).
Genotoxicity was determined using the comet assay.
Sensitivity of p53, a crucial target gene for transition of
adenoma to carcinoma, was studied with FISH.
Expressions of GST isoenzymes, some of which deactivate
HNE, were determined as GST-activity and GSTP1 protein
levels. Genotoxic impact of HNE was compared in buty-
rate-treated and non-treated cells using the comet assay.
Responses were compared with primary human colon
cells and to a differentiated clone of HT29.
The main results were:
. both HNE and H2O2 were clearly genotoxic in human
colon cells. HNE was more genotoxic in LT97 than
in HT29 clone19A and primary human colon cells.
DNA regions that were labelled with the p53-specific
probe migrated more efficiently in to the comet tail
than the majority of the global DNA;
. butyrate (4 mM) induced ERK1/2 phosphorylation after
5–30 min. After 24–72 h incubation with butyrate, and
some selected mixtures from fermentation samples,
GST mRNA, GSTP1 protein, GSTP1 activity and
total protein were increased (1·2- to 2·5-fold) and gluta-
thione levels were maintained. Moreover, a marked
reduction of HNE-induced genotoxicity was caused
by pre-incubation with butyrate and fermentation
samples from selected dietary fibres.
HNE was more genotoxic in human adenoma cells than
in tumour cells, and this was partly due to the different
GST expression-levels. P53-labelled DNA regions were
more sensitive to HNE than global DNA (Scha¨ferhenrich
et al. 2003a,b). Recent studies show that butyrate could
play a role in the early and later stages of cancer prevention
by reducing exposure to this and other relevant risk factors
via induction of different GST in transformed and non-
transformed human colon cells (Ebert et al. 2003).
DNA adducts
The accumulation of DNA damage (breaks, oxidative
damage, adduct formation) may be indicative of increased
CRC risk. DNA adducts are formed by genotoxic com-
pounds binding covalently to DNA, and if not repaired,
they can lead to mutations, e.g. G:C! T:A transversions.
They appear to indicate internal dose exposure to geno-
toxic agents and levels are affected by diet (Palli et al.
2000) and genotype (Matullo et al. 2003).
Professor Sheila Bingham presented the results from
several FSA-funded projects investigating both the effect
of meat consumption on endogenous N-nitrosation in the
colon, and the relationship between diet and the formation
of 1,N2 malondialdehyde–deoxyguanosine adducts and
N7-methyldeoxyguanosine and O 6-carboxymethylguanine
adducts in the colon. N-nitroso compounds are found in
the colon and are formed endogenously, because the
amines and amides produced primarily by bacterial decar-
boxylation of amino acids can be N-nitrosated in the
presence of a nitrosating agent. A number of facultative
and anaerobic colonic bacteria are able to catalyse the for-
mation of N-nitroso compounds at an optimum pH of 7·5.
In the anaerobic large bowel, nitrate is reduced to nitrite
during dissimilatory nitrate metabolism by the colonic
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flora. Supplements of nitrate have therefore been shown to
elevate faecal N-nitroso compound levels.
Epidemiological studies consistently suggest that high
red meat consumption (e.g. 120 g/d) is associated with an
increased risk of CRC (Norat et al. 2002). Whether
increased nitrogenous residues from red meat increase
endogenous N-nitrosation was examined by feeding
increased levels of red meat (0–420 g/d) and measuring
apparent total N-nitroso compounds in faecal samples in
a series of studies of volunteers maintained under
controlled conditions. A consistent dose–response was
observed to red meat consumption, but not to white meat
consumption (Bingham et al. 1996, 2002; Silvester et al.
1997; Hughes et al. 2001, 2002). While red meat diets
increased faecal apparent total N-nitroso compounds, the
equivalent amount of protein from eggs, milk, cheese and
vegetable protein has no effect; furthermore, there appears
to be a specific effect of haem-Fe whereas inorganic Fe has
no effect (Cross et al. 2003). Under certain conditions,
haems are known to be nitrosated, and act as nitrosating
agents. The formation of N-nitrosoarginine by haem
enzymes under anaerobic conditions has also been demon-
strated by Hirst & Goodin (2000).
To determine whether faecal N-nitroso compounds are
candidates in explaining the association between meat
and colon cancer risk, the genotoxic effects of increased
N-nitrosation is presently being investigated: the effects
of faecal water from low v. high meat diets on strand
breaks (comet test), mouse lymphoma cell line L5178Y
mutations and p53 mutations are being investigated in a
yeast mutation assay. The chemical composition of
N-nitroso compounds is being investigated by liquid chro-
matography–MS. A method for isolating exfoliated cells
from faeces has been developed (Bandaletova et al.
2002; Davies et al. 2002) and the link between diet and
the presence of 1,N2 malondialdehyde–deoxyguanosine
adducts in colonic biopsy samples investigated, but no
relationship was found (Leuratti et al. 2002). This was
probably due to the low 1,N2 malondialdehyde–deoxygua-
nosine adduct levels found in blood that cannot be reliably
measured. In previous and ongoing work the presence of
N7-methyldeoxyguanosine and O 6-carboxymethylguanine
adducts in blood, colonic mucosa biopsy samples and
exfoliated cells is being investigated in order to develop
exposure and/or intermediate risk markers of meat
exposure and large-bowel cancer risk.
Discussion
‘Biomarkers’ can be explicitly biomarkers of exposure (to
dietary components) or biomarkers of risk (surrogate end
points of disease), but are not necessarily both. The objec-
tive is to identify measurements that can be validated as
both biomarkers of exposure and disease risk. The
development of appropriate, feasible markers of exposure,
e.g. for vegetable consumption, remains important, how-
ever, as evidence of the relationship between diet and
CRC from epidemiological studies is not always consistent.
For the development of diet-related surrogate end points
of CRC, it is important to ascertain whether the test of an
association between an exposure and a surrogate end point
will reliably indicate whether there is an association
between the exposure and cancer. Three statistical con-
ditions are needed to establish this: (1) the surrogate end
point is associated with cancer; (2) the exposure is associ-
ated with the surrogate end point; (3) the surrogate end
point ‘mediates’ the association between exposure and
cancer. An important consideration, as well as reproduci-
bility and variability, is whether the magnitude of the
association between exposure and the surrogate end point
predicts the magnitude of the association between exposure
and cancer.
Relevant changes will probably occur in ‘flat’ colonic
mucosa, i.e. in advance of the development of lesions
such as aberrant crypt foci or polyps; these early changes
may be apparent as ‘field effects’ that may be amenable
to detection. Events hypothesised to precede clinical
lesions may be reversible by appropriate dietary or other
manoeuvres. Emphasis, therefore, should be given to
early stage indicators that are underpinned by a mechanis-
tic understanding of the carcinogenesis process. Cancer is a
genetic disease and surrogate end points need to be related
to fundamental processes, e.g. the switching off of tumour
suppresser genes by mutation or silencing; equally,
modulation by diet must also be demonstrated.
The DNA alterations that underlie CRC are hetero-
geneous. Case–control studies that have investigated
associations between specific mutations and/or alterations
in CRC patients and dietary factors point to different path-
ways in colorectal carcinogenesis in which dietary factors
may be involved, e.g. different dietary factors are associ-
ated with mutations in k-ras (Slattery et al. 2000), p53
(Slattery et al. 2002) and adenomatous polyposis coli
(Diergaarde et al. 2003). There may be, therefore, need
to detect alterations in a number of genes, and to consider
several biomarkers in combination.
The importance of using human colonic mucosal biop-
sies was noted. It will be important to investigate parallels
with surrogate tissues to determine the extent to which
more accessible tissues can be used. The development of
non-invasive surrogate end points was also highlighted,
and the use of exfoliated mucosal cells in stool (e.g. for
the extraction and amplification of colorectal epithelial
DNA) for determining biomarkers may have great
potential.
Last, the workshop highlighted the need to clarify the
exposure of colonic mucosa to food components, i.e.
tissue specificity in response to food components. A better
understanding of the mechanisms by which nutrients can
affect the tissue could underpin biomarker development.
Recommendations
. The validation of current putative diet-related surrogate
end points for CRC and the development of novel ones,
particularly in the emerging fields of proteomics, geno-
mics and epigenomics.
. To introduce into CRC-screening protocols measures of
dietary exposure and the collection and validation of
putative diet-related surrogate end points.
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